Panbela Therapeutics (PBLA) Q2 2024 earnings summary

Executive summary

• The Phase III ASPIRE trial for ivospemin in metastatic pancreatic cancer continues after a positive DSMB safety review, with enrollment progressing faster than anticipated and full enrollment expected by Q1 2025; interim analysis is delayed to early 2025 due to prolonged patient survival, suggesting potential efficacy benefit.

• Additional clinical programs include FAP, PACES, and multiple phase II and I trials in various cancer indications and type 1 diabetes, with several milestones expected in the second half of 2024 and 2025.

• Eflornithine pediatric neuroblastoma program achieved FDA approval, is being commercialized by US WorldMeds, and generated $775,000 in Q2, with further milestone payments possible.

• Panbela's common stock was delisted from Nasdaq in April 2024, is now quoted on OTCQB, and the company has applied for relisting.

• Positive preclinical and clinical data were presented at major conferences, and new US and Canada patents were issued for fixed dose combination therapies.

Financial highlights

• Q2 2024 net loss was $7.1 million ($1.47 per diluted share), compared to $5.8 million ($159.15 per diluted share) in Q2 2023, with operating expenses rising to $8.1 million and R&D expenses increasing 65.3% to $7.0 million, while G&A expenses decreased 32.7% to $1.1 million.

• Cash as of June 30, 2024, was $59,000, with total current assets of $0.8 million and current liabilities of $16.8 million; working capital deficit widened to $16.0 million.

• Net cash used in operating activities was $10.4 million for the first half of 2024, down from $15.5 million in the prior year period.

• The company raised $8.1 million from a public offering in January 2024 and made a $1.0 million loan repayment.

• Weighted average shares outstanding increased to 4.85 million as of June 30, 2024.

Outlook and guidance

• Full enrollment of the ASPIRE trial is expected by Q1 2025, with interim analysis projected for early 2025 due to lower event rates and prolonged survival.

• Multiple clinical milestones are anticipated in the second half of 2024, including trial initiations and data publications.

• PACES trial data readout is expected in the second half of 2026.

• The company needs to raise additional capital immediately to continue operations and execute its business plan.

• If unable to secure financing, operations may be scaled back, delayed, or ceased.